Friday 6 November 2026 Export ALKS’s income statement to Excel — free account

Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue: +21.8%
EPS: −80.6%
Free cash flow: +6.78%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

45.40 0.86 +1.93%

Follow ALKS

Alert me

Market cap: $7.5B
P/E: 0.0×
Fwd P/E: −85.9×
Dividend yield: —
F-score: 7/9
Altman Z: 5.33
Beneish M: −3.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Alkermes plc 10-Q filed Nov 3, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Nov 3, 2026 · accepted 9:20 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Jul 28, 2026: no changes